Drug intelligence / Profile preview

BBC-1501

Development stage: Phase 1
Lead developer: Benobio
Modality: Small Molecules
Administration: Intravitreal

Overview

BBC-1501 is a small molecule drug developed by Benobio for the treatment of eye diseases, specifically wet age-related macular degeneration (nAMD). It acts as an inhibitor of bromodomain and extraterminal domain proteins (BET), which are epigenetic regulators implicated in inflammation and pathological angiogenesis. The drug is currently in Phase 1 clinical trials to evaluate its safety and tolerability when administered via intravitreal injection in patients with neovascular age-related macular degeneration. Its mechanism targets BET proteins to potentially reduce disease progression associated with abnormal blood vessel growth in the retina[1][2][3][4][5].

Other names: BBC 1501BBC1501BBC-1501BBRP 11001BBRP11001BBRP-11001

Targets

BET (BET family proteins)

Beyond the preview

Go deeper on BBC-1501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBC-1501.

Explore the full profile